About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 709145, 12 pages
http://dx.doi.org/10.1155/2013/709145
Research Article

Immunocytochemical Characterization of Alzheimer Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine

1Department of Neurosciences, EuroEspes Biotechnology, 15165 La Coruna, Spain
2Department of Human Sciences, Texas A&M University-Kingsville, Kingsville, TX, USA
3Atlas Pharmaceuticals, Sunnyvale, CA, USA
4National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
5Medical Center of the Administration of the President of the Republic of Kazakhstan, Astana, Kazakhstan
6EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, 15165 La Coruna, Spain
7“GALLY” International Biomedical Research Consulting LLC, San Antonio, TX, USA
8Department of Health Science and Healthcare Administration, University of Atlanta, Atlanta, GA, USA

Received 10 April 2013; Revised 11 June 2013; Accepted 2 July 2013

Academic Editor: Aaron Dumont

Copyright © 2013 Iván Carrera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Tanzi and L. Bertram, “Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective,” Cell, vol. 120, no. 4, pp. 545–555, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Blennow, M. J. de Leon, and H. Zetterberg, “Alzheimer's disease,” The Lancet, vol. 368, no. 9533, pp. 387–403, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Selkoe, “Toward a remembrance of things past: deciphering Alzheimer disease,” Harvey Lectures, vol. 99, pp. 23–45, 2003. View at Scopus
  4. L. Bertram, M. McQueen, K. Mullin, D. Blacker, and R. Tanzi, “The AlzGene database,” Alzheimer Research Forum, 2012, http://www.alzgene.org.
  5. R. Cacabelos, R. Martínez, L. Fernández-Novoa et al., “Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics,” International Journal of Alzheimer's Disease, vol. 2012, Article ID 518901, 37 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Cacabelos and R. Martínez-Bouza, “Genomics and pharmacogenomics of dementia,” CNS Neuroscience and Therapeutics, vol. 17, no. 5, pp. 566–576, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Cacabelos, L. Fernandez-Novoa, V. Lombardi, Y. Kubota, and M. Takeda, “Molecular genetics of Alzheimer's disease and aging,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 27, pp. 1–573, 2005. View at Scopus
  8. D. M. Walsh and D. J. Selkoe, “Deciphering the molecular basis of memory failure in Alzheimer's disease,” Neuron, vol. 44, no. 1, pp. 181–193, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Maier, T. J. Seabrook, N. D. Lazo et al., “Short amyloid-β (Aβ) immunogens reduce cerebral Aβ load and learning deficits in an Alzheimer's disease mouse model in the absence of an Aβ-specific cellular immune response,” Journal of Neuroscience, vol. 26, no. 18, pp. 4717–4728, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Dodart, K. R. Bales, K. S. Gannon et al., “Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model,” Nature Neuroscience, vol. 5, no. 5, pp. 452–457, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Games, D. Adams, R. Alessandrini et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein,” Nature, vol. 373, no. 6514, pp. 523–527, 1995. View at Scopus
  12. K. Hsiao, P. Chapman, S. Nilsen et al., “Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice,” Science, vol. 274, no. 5284, pp. 99–102, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Sturchler-Pierrat, D. Abramowski, M. Duke et al., “Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 24, pp. 13287–13292, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. E. McGowan, S. Sanders, T. Iwatsubo et al., “Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes,” Neurobiology of Disease, vol. 6, no. 4, pp. 231–244, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Holcomb, M. N. Gordon, E. Mcgowan et al., “Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes,” Nature Medicine, vol. 4, no. 1, pp. 97–100, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Chishti, D. Yang, C. Janus et al., “Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695,” The Journal of Biological Chemistry, vol. 276, no. 24, pp. 21562–21570, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. M. N. Gordon, L. A. Holcomb, P. T. Jantzen et al., “Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse,” Experimental Neurology, vol. 173, no. 2, pp. 183–195, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Trinchese, S. Liu, F. Battaglia, S. Walter, P. M. Mathews, and O. Arancio, “Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice,” Annals of Neurology, vol. 55, no. 6, pp. 801–814, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. J. L. Jankowsky, D. J. Fadale, J. Anderson et al., “Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase,” Human Molecular Genetics, vol. 13, no. 2, pp. 159–170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Lu, T. Mamiya, L. L. Lu et al., “Silibinin prevents amyloid β peptide-induced memory impairment and oxidative stress in mice,” The British Journal of Pharmacology, vol. 157, no. 7, pp. 1270–1277, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. L. M. Refolo, M. A. Pappolla, B. Malester et al., “Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model,” Neurobiology of Disease, vol. 7, no. 4, pp. 321–331, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. N. V. Patel, M. N. Gordon, K. E. Connor et al., “Caloric restriction attenuates Aβ-deposition in Alzheimer transgenic models,” Neurobiology of Aging, vol. 26, no. 7, pp. 995–1000, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. P. A. Adlard, V. M. Perreau, V. Pop, and C. W. Cotman, “Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease,” Journal of Neuroscience, vol. 25, no. 17, pp. 4217–4221, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Schenk, R. Barbour, W. Dunn et al., “Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse,” Nature, vol. 400, no. 6740, pp. 173–177, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Bard, R. Barbour, C. Cannon et al., “Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 4, pp. 2023–2028, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. N. C. Carty, D. M. Wilcock, A. Rosenthal et al., “Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice,” Journal of Neuroinflammation, vol. 3, article 11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Morgan, “Immunotherapy for Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 9, pp. 425–432, 2006.
  28. G. Mamikonyan, M. Necula, M. Mkrtichyan et al., “Anti-Aβ1-11 antibody binds to different β-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers,” The Journal of Biological Chemistry, vol. 282, no. 31, pp. 22376–22386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. L. A. Kotilinek, B. Bacskai, M. Westerman et al., “Reversible memory loss in a mouse transgenic model of Alzheimer's disease,” Journal of Neuroscience, vol. 22, no. 15, pp. 6331–6335, 2002. View at Scopus
  30. D. Morgan, “Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice,” Neurochemistry International, vol. 49, no. 2, pp. 190–194, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Orgogozo, S. Gilman, J. Dartigues et al., “Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization,” Neurology, vol. 61, no. 1, pp. 46–54, 2003. View at Scopus
  32. J. A. R. Nicolll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller, “Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report,” Nature Medicine, vol. 9, no. 4, pp. 448–452, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Ferrer, M. Boada, M. Sánchez-Guerra, M. Rey, and F. Costa-Jussá, “Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease,” Brain Pathology, vol. 14, pp. 11–20, 2004.
  34. S. Gilman, M. Koller, R. S. Black et al., “Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial,” Neurology, vol. 64, no. 9, pp. 1553–1562, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Masliah, L. Hansen, A. Adame et al., “Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease,” Neurology, vol. 64, no. 1, pp. 129–131, 2005. View at Scopus
  36. S. Guénette, “Mechanisms of Aβ clearance and catabolism,” NeuroMolecular Medicine, vol. 4, no. 3, pp. 147–160, 2003. View at Publisher · View at Google Scholar
  37. N. Andreasen, M. Sjögren, and K. Blennow, “CSF markers for Alzheimer's disease: total tau, phospho-tau and Aβ42,” World Journal of Biological Psychiatry, vol. 4, no. 4, pp. 147–155, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. Z. Suo, A. A. Cox, N. Bartelli et al., “GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment,” Neurobiology of Aging, vol. 28, no. 12, pp. 1873–1888, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Sun, X. V. Nguyen, and G. Bing, “Comparative analysis of an improved thioflavin-S stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections,” Journal of Histochemistry and Cytochemistry, vol. 50, no. 4, pp. 463–472, 2002. View at Scopus
  40. T. Bussière, F. Bard, R. Barbour et al., “Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance,” The American Journal of Pathology, vol. 165, no. 3, pp. 987–995, 2004. View at Scopus
  41. T. Tomiyama, S. Matsuyama, H. Iso et al., “A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo,” Journal of Neuroscience, vol. 30, no. 14, pp. 4845–4856, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Chen, K. S. Chen, D. Kobayashi et al., “Active β-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of β-amyloid,” Journal of Neuroscience, vol. 27, no. 10, pp. 2654–2662, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. H. J. Fu, B. Liu, J. L. Frost, and C. A. Lemere, “Amyloid-β immunotherapy for Alzheimer's disease,” CNS and Neurological Disorders—Drug Targets, vol. 9, no. 2, pp. 197–206, 2010. View at Scopus
  44. M. Jones, J. L. Cordell, A. D. Beyers, A. G. D. Tse, and D. Y. Mason, “Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies,” Journal of Immunology, vol. 150, no. 12, pp. 5429–5435, 1993. View at Scopus
  45. S. Dudal, P. Krzywkowski, J. Paquette et al., “Inflammation occurs early during the Aβ deposition process in TgCRND8 mice,” Neurobiology of Aging, vol. 25, no. 7, pp. 861–871, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. M. E. Calhoun, P. Burgermeister, A. L. Phinney et al., “Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 24, pp. 14088–14093, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Terai, A. Iwai, S. Kawabata et al., “β-amyloid deposits in transgenic mice expressing human β-amyloid precursor protein have the same characteristics as those in Alzheimer's disease,” Neuroscience, vol. 104, no. 2, pp. 299–310, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Ruan, Z. Kang, G. Pei, and Y. Le, “Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease,” Current Alzheimer Research, vol. 6, no. 6, pp. 531–540, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Solomon, R. Koppel, E. Hanan, and T. Katzav, “Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 1, pp. 452–455, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Solomon, R. Koppel, D. Frankel, and E. Hanan-Aharon, “Disaggregation of Alzheimer β-amyloid by site-directed mAb,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 8, pp. 4109–4112, 1997. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Bard, C. Cannon, R. Barbour et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,” Nature Medicine, vol. 6, no. 8, pp. 916–919, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. B. J. Bacskai, S. T. Kajdasz, M. E. McLellan et al., “Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy,” Journal of Neuroscience, vol. 22, no. 18, pp. 7873–7878, 2002. View at Scopus
  53. P. Das, V. Howard, N. Loosbrock, D. Dickson, M. P. Murphy, and T. E. Golde, “Amyloid-β immunization effectively reduces amyloid deposition in FcRγ-/- knock-out mice,” Journal of Neuroscience, vol. 23, no. 24, pp. 8532–8538, 2003. View at Scopus
  54. I. Klyubin, D. M. Walsh, C. A. Lemere et al., “Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo,” Nature Medicine, vol. 11, no. 5, pp. 556–561, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Akiyama, S. Barger, S. Barnum et al., “Inflammation and Alzheimer's disease,” Neurobiology of Aging, vol. 21, no. 3, pp. 383–421, 2000. View at Publisher · View at Google Scholar
  56. K. D. Bornemann and M. Staufenbiel, “Transgenic mouse models of Alzheimer's disease,” Annals of the New York Academy of Sciences, vol. 908, pp. 260–266, 2000. View at Scopus
  57. M. N. Gordon, L. A. Holcomb, P. T. Jantzen et al., “Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse,” Experimental Neurology, vol. 173, no. 2, pp. 183–195, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. M. T. Heneka, H. Wiesinger, L. Dumitrescu-Ozimek, P. Riederer, D. L. Feinstein, and T. Klockgether, “Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease,” Journal of Neuropathology and Experimental Neurology, vol. 60, no. 9, pp. 906–916, 2001. View at Scopus
  59. R. Minkeviciene, J. Ihalainen, T. Malm et al., “Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice,” Journal of Neurochemistry, vol. 105, no. 3, pp. 584–594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Koistinaho, S. Lin, X. Wu et al., “Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides,” Nature Medicine, vol. 10, no. 7, pp. 719–726, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Duyckaerts, M. Potier, and B. Delatour, “Alzheimer disease models and human neuropathology: similarities and differences,” Acta Neuropathologica, vol. 115, no. 1, pp. 5–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Matsuoka, M. Picciano, B. Maleste et al., “Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease,” The American Journal of Pathology, vol. 158, no. 4, pp. 1345–1354, 2001. View at Scopus
  63. S. Itagaki, P. L. McGeer, H. Akiyama, S. Zhu, and D. Selkoe, “Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease,” Journal of Neuroimmunology, vol. 24, no. 3, pp. 173–182, 1989. View at Scopus
  64. C. W. Cotman, A. J. Tenner, and B. J. Cummings, “β-amyloid converts an acute phase injury response to chronic injury responses,” Neurobiology of Aging, vol. 17, no. 5, pp. 723–731, 1996. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Mrak, J. Sheng, and W. Griffin, “Correlation of astrocytic S100b expression with dystrophic neurites in amyloid plaques of Alzheimer's disease,” Journal of Neuropathology and Experimental Neurology, vol. 55, no. 4, pp. 273–279, 1996. View at Publisher · View at Google Scholar
  66. T. Town, M. Vendrame, A. Patel et al., “Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's β-amyloid1–42,” Journal of Neuroimmunology, vol. 132, no. 1-2, pp. 49–59, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Muhs, D. T. Hickman, M. Pihlgren et al., “Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 23, pp. 9810–9815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Kitazawa, S. Oddo, T. R. Yamasaki, K. N. Green, and F. M. LaFerla, “Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease,” Journal of Neuroscience, vol. 25, no. 39, pp. 8843–8853, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Panza, V. Frisardi, V. Solfrizzi et al., “Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies,” Immunotherapy, vol. 4, no. 2, pp. 213–238, 2012. View at Publisher · View at Google Scholar · View at Scopus